Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Merck Sharp & Dohme LLC
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center ( Site 0181) | Gilbert, Arizona, United States | Recruiting |
| The University of Arizona Cancer Center - North Campus ( Site 0163) | Tucson, Arizona, United States | Recruiting |
| Providence St. Jude Medical Center ( Site 0106) | Fullerton, California, United States | Recruiting |
| VA Long Beach Healthcare System ( Site 0199) | Long Beach, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center ( Site 0205) | Los Angeles, California, United States | Recruiting |
| UCLA Jonsson Comprehensive Cancer Center ( Site 0135) | Los Angeles, California, United States | Recruiting |
| UCSF Medical Center at Mission Bay ( Site 0178) | San Francisco, California, United States | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0151) | Aurora, Colorado, United States | Recruiting |
| UCHealth Memorial Hospital Central ( Site 0125) | Colorado Springs, Colorado, United States | Recruiting |
| Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) | Greeley, Colorado, United States | Recruiting |
| Centura Health - St. Anthony North Health Campus ( Site 0189) | Westminster, Colorado, United States | Recruiting |
| Yale University School of Medicine ( Site 0201) | New Haven, Connecticut, United States | Recruiting |
+ 226 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06623422